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am a Senior working on a B.S. in Biology.  I am 
Executive Vice-President of the National 
Soc ie ty  o f  Co l l eg ia te  Scholars  (2008-
2009) and an AMSTEMM Research Fel low. 
Also, I have received a eUreKa! Research Grant
My future plans are to attend medical school.  This 
submission relates closely to my future plans because 
I am highly interested in neuroscience, gerontology, 
and how Alzheimer’s disease (AD) significantly affects 
the character of the person who is diagnosed with 
it.  I am intrigued by this disease’s power to radically 
change a person’s life.  Not only does Alzheimer’s disease cause severe 
memory loss, this disease also causes the ruthless diminishment of 
cognitive thinking skills.  Some people who have late-onset AD (LAD) 
lose the ability to perform simple, daily tasks normal people take for 
granted, such as the ability to speak or to remember one’s own name. 
By working with Dr. Butterfield, I have gained much insight and 
knowledge regarding AD.  I was privileged to work with Dr. Butterfield’s 
research group, considering that I had no prior research laboratory experience. 
Dr. Butterfield mentored me through this research of AD for over a year, and 
he has given me great advice on not only school-related subjects, but also on 
life in general.  He is someone to whom I can go for advice on applications to 
graduate school, on study questions in biology, chemistry, and biochemistry, 
and on what I should do to make myself a stronger student inside and outside 
the classroom.  I am honored that someone as prestigious as Dr. Butterfield 
was able to give me a hands-on experience in science.  In addition, I have 
gained many friends.  All of the graduate students, post-doctorates, and 
research associates always offer a lending hand, and no is ever excluded. 
My most important extracurricular activities are volunteering at St. Joseph 
Hospital, summer clinical experiences with physicians from Harlan Appalachian 
Regional Healthcare Hospital, playing the piano, exercising (which is extremely 
important in the prevention of Alzheimer’s disease), cooking, and baking. 
This work has been presented at the Kentucky Academy of Science, the 
AMSTEMM Research Colloquium, the National Conference on Undergraduate 
Research (NCUR), and the UK Showcase of Undergraduate Scholars.  This 
research work will be combined with the work of Dr. Sultana and plans 
for submission for publication in a professional journal are underway. 
As a research student on AD, I am quite optimistic that someday AD 
will be a thing of the past.  This success can and will be achieved as research 
advances and new unknowns are solved.  I believe that researchers will be 
capable of solving all of the unknown facets of this disease and will be able to 
synthesize a definite cure 
one day.  That is my hope, 
and I want to be a part of 
the solution.  Ultimately, 
I wish that everyone can 
attain a full, satisfiying 
life — a life filled with 
memories unforgotten.
The study completed by Ms. Tiu is outstanding.  It is rare 
that an undergraduate is allowed to use human brain 
specimens, but Ms. Tiu is so careful in her work that 
an exception was made for her.  Ms. Tiu found levels of 
key brain proteins are altered in the brains of subjects 
with mild cognitive impairment (MCI), arguably the 
earliest detectable form of Alzheimer’s disease (AD). 
Our laboratory’s previous research had shown that 
oxidative damage to the brain in MCI is present.  The 
proteins whose levels are altered in MCI likely reflect 
this oxidative damage, and these proteins are involved 
in signaling and/or neuroinflammation.  Consequently, 
the significance of this research 
is that the altered levels of these 
proteins determined by Ms. Tiu 
in the brains of subjects with 
MCI strongly support the notion 
that oxidative stress-induced 
brain protein alterations are 
important in the progression 
of AD.  Ms. Tiu conducted 
this research and wrote the 
paper by herself, with some 
editing assistance from me.
I
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Abstract
The purpose of this study was to measure the expression 
levels of key signaling proteins in brain tissue from 
subjects with mild cognitive impairment (MCI) 
compared to control subjects.  MCI is considered to be 
the beginning phase of Alzheimer’s disease (AD).  Tumor 
necrosis factor alpha (TNF-α), nuclear factor kappa beta 
(NF-κβ), phospho Bad (pBad), and ubiquitin C-terminal 
hydrolase-L1 (UCH-L1) are four of the proteins that were 
investigated.  Trends of either decreases or increases in 
protein expression levels in MCI vs. control brain were 
investigated.  Western blot analysis was used in order 
to identify these trends.  These signaling protein levels 
are reportedly up-regulated or down-regulated in the AD 
brain; consequently, investigating protein expression 
levels in MCI brain may provide insight into how these 
proteins contribute to the transition from MCI to AD. 
Introduction
Alzheimer’s disease (AD) is a disheartening illness to not 
only those who have developed it, but also to family and 
friends of AD patients.  According to current research, 
it is estimated that 14-16 million Americans and more 
than 22 million people around the world are expected 
to develop AD in the near future, unless an intervention 
can be developed (Butterfield et al., 2007).  However, 
that much-anticipated intervention is closer to reality 
due to the efforts of Professor Butterfield and his team. 
Mild Cognitive Impairment (MCI) is considered 
to be the “intermediate stage between normal aging 
and the AD brain” (Butterfield et al., 2007).  In the 
early stages of MCI, many people go on living their 
daily lives quite normally.  However, in amnestic MCI 
there is a noticeable decline of memory compared to 
prior years, but there are no signs of dementia in the 
early stages.  Still, some researchers consider MCI to 
be the earliest stage of AD.  Using redox proteomics to 
investigate molecular aspects of AD and MCI, Professor 
Butterfield’s team has tracked and recorded the degrading 
effects of oxidative stress (Butterfield et al., 2007). 
Earlier studies have illustrated the importance of 
oxidative stress in the pathogenesis of AD.  Oxidative 
stress is caused by an imbalance between the production 
of toxic reactive oxygen species (ROS) and the 
body’s antioxidant systems.  Protein oxidation can 
lead to extracellular amyloid plaques, intracellular 
neurofibrillary tangles, oligomers of amyloid β-peptide 
(Aβ), and synapse loss (Butterfield et al., 2007). 
The Aβ (1-42) peptide is the peptide of interest in 
the study of AD pathology.  Aβ (1-42) is a peptide 
that is derived from the proteolytic cleavage of a 
Type I integral membrane protein known as amyloid 
precursor protein (APP) and is thought to underlie 
the pathogenesis of AD (Butterfield et al., 2007). 
Protein oxidation causes notable adverse effects. 
Oxidation of proteins can cause protein dimerization, 
in which two molecules of the same chemical 
composition can form a condensation product.  In 
addition, protein oxidation can lead to denaturation 
of proteins, a process in which a protein unfolds from 
its usual structure, and its normal conformation is 
lost.  This process is detrimental because the unfolding 
allows the hydrophobic (“water-fearing”) amino acid 
residues to be exposed to the aqueous environment. 
This exposure can lead to a loss of structural or 
functional activity and cause protein aggregation, such 
as tau aggregation that is evident in the AD brain. 
Tau aggregation is responsible for forming the 
neurofibrillary tangles, while senile plaques are 
composed of extracellular, fibrillar Aβ (1-42) that 
histopathologically characterize the AD brain. The senile 
plaques are associated with activated astrocytes and 
copious amounts of microglia at the site of deposition 
of Aβ (1-42) in AD (Bernhardi and Eugenin, 2004). 
Furthermore, the activation of the inflammatory 
response is thought to be crucial in quantifying the 
rate of the neurodegenerative process (McGeer and 
McGeer, 1998).  β-Amyloid activates glia to synthesize 
an assortment of inflammatory factors such as 
tumor necrosis factor-alpha (TNF-α), reactive oxygen 
species (ROS), nitric oxide (NO) and inducible nitric 
oxide synthase (iNOS), which may increase the 
rate of the development of AD (Jiang et al., 2007).
Materials
All chemicals used were purchased from Sigma-Aldrich 
(St. Louis, MO) with the exception of nitrocellulose 
membranes (Bio-Rad, Hercules, CA), electrophoretic 
transfer system (Trans-blot Semi-dry Transfer Cell; Bio-
Rad), and Western blotting (Calbiochem, LA Jolla, CA). 
Subjects
The University of Kentucky Rapid Autopsy Program 
of the Alzheimer’s Disease Clinical Center (UK ADC) 
provided frozen hippocampus samples from MCI 
subjects and age-matched controls. The patients were 
diagnosed with probable MCI according to criteria 
produced by the National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS) and the 
Alzheimer’s Disease and Related Disorders Association. 
The control subjects did not have any neurological 
disorders nor did they have a history of dementia. 
They had undergone annual mental status testing and 
semiannual physical and neurological examinations as 
part of the UK ADC normal volunteer longitudinal aging 
study.  Table 1 describes the background of the patients. 
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β
Sample preparation
The brain tissues (hippocampus) from controls and 
MCI subjects were homogenized in ice-cold isolation 
buffer containing 10mM Hepes buffer, 137mMNaCl, 
4.6 mM KCl, 1.1 mM KH2PO4, and 0.6 mM MgSO4, 
as well as proteinase inhibitors leupeptin (0.5 mg/
ml) and pepstatin (0.7 mg/ml).  Homogenates were 
centrifuged at 14,000 g for 10 min to remove debris. 
The supernatant was extracted to determine the 
total protein concentration by the BCA method. 
Twenty µl of either 150 µg or 100 µg of control 
and MCI samples from the hippocampus (one of the 
first regions of the brain to suffer damage from AD) 
were used in the 1D Western blots. 1D Western Blots 
were used to determine the protein expression levels 
in control and MCI brain tissues.  Gel electrophoresis 
was utilized to separate the denatured control and MCI 
brain proteins, and the proteins were then transferred 
to a nitrocellulose membrane.  Primary and secondary 
antibodies detected the proteins that were on the blot.
The science underlying tagging antibodies is actually 
quite simple.  First, an animal such as a rabbit is injected 
with a protein, such as TNF-α.  The rabbit’s immune system 
then produces antibodies against the foreign protein, 
TNF-α.  The antibodies are then collected and are called 
primary antibodies.  A second animal, such as a goat, 
is injected with the primary antibodies that the rabbit’s 
immune system created.  The goat’s immune system then 
creates antibodies against the newly injected primary 
antibodies and the secondary antibodies are thus created. 
Western blotting analysis
In the process of Western blotting, a primary antibody 
is added to the nitrocellulose membrane in order to tag 
the protein of interest, such as TNF-α.  The secondary 
antibody then tags and recognizes the primary 
antibodies.  Specific substrates, 5-bromo-4-chloro-3-
indolyl-phosphate and nitroblue tetrazolium (BCIP 
and NBT), are then used to catalyze the reaction 
and develop the blot so that the proteins can be 
seen.  A purple color is the result of the reaction.  A 
distinctive band of the specific protein is expected to 
show up first, especially with monoclonal antibodies. 
There are two different kinds of antibodies used in 
this project — monoclonal and polyclonal antibodies. 
Monoclonal antibodies are specific for certain amino 
acid sequences and their motifs.  A blot that uses 
monoclonal antibodies usually shows fewer bands 
than polyclonal because monoclonal antibodies are 
more specific to the particular protein’s amino acid 
sequence.  With the case of polyclonal antibodies, more 
bands show up because repeating amino acid motifs 
in proteins other than the particular protein of interest 
(TNF-α for example) are tagged as well.  However, 
because each protein has its own molecular weight, 
determining which band belongs to the protein of 
interest is not difficult. The blots are then scanned with 
Adobe Photoshop and quantified with Scion Image (PC 
version of Macintosh-compatible NIH Image) software.
Tumor Necrosis Factor-Alpha, TNF-α
Tumor necrosis factor-alpha (TNF-α) is a member 
of a cytokine family that can cause cell apoptosis 
(programmed cell death) and cellular proliferation 
and differentiation.  Cellular differentiation can be 
observed in macrophages, inflammatory cells that 
originate from white blood cells.  TNF-α  is produced 
by specific cells of the immune system in response 
to adverse conditions, such as exposure to ionizing 
radiation, elevated temperature, viral infection, or 
toxic chemical agents such as those used in cancer 
chemotherapy (Karp, G., 2005; Tangpong et al., 
2006).  TNF-α is a pro-inflammatory cytokine that 
participates in inflammation, cell survival, and cell 
death processes (Gomez-Chiarri et al., 1994) and can 
trigger cell death through cell apoptosis and necrosis. 
This particular cytokine is a signaling protein that 
is secreted from immune system cells that ultimately 
changes the action of other immune cells.  TNF-α 
regulates immune cells and causes inflammatory re-
sponses.  These inflammatory responses are necessary 
in order to defend the body against pathogens.  How-
ever, increased levels of inflammation are evident in 
neurodegenerative disorders and are implicated in the 
etiology of Alzheimer’s disease, Parkinson’s disease, and 
ischemia (Lovell et al., 1998; Liao et al., 2001; Gao et 
al., 2002).  In mice treated with pro-oxidant adriamycin 
or in AD brain, neuroinflammation arbitrated from glia 
overproduction or dysfunctional regulation of TNF-α 
Table 1. Characteristics of control and MCI patients (mean ± SD).
1. MCI: mild cognitive impairment
2. The standard, six-stage description of 
a patient’s level of AD, from extremely 
mild to full-blown dementia, named for 
the German researcher who developed 
the scale. 
Demographic variables        Control Subjects           MCI Subjects1
Number of subjects        7             7
Gender (male/female)        3/4                         3/4
Postmortem Interval (hours)    2.87±1.14                        3.125±1.033
Brain weight (grams)        1260±120                             1120±61
Braak2 stage         I-II                          III-V
Figure 1. TNF-α Protein Levels in Control and MCI Hippocampus
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is observed (Jiang et al., 2007; Tangpong et al., 2008). 
Mechanism
In its normal mechanism of signaling cell apoptosis, 
TNF-α first binds to its receptor, either TNFR1 or 
TNFR2.  TNFR1 is the receptor that is constitutively 
expressed in most tissues.   The activated receptor then 
binds TRADD and FADD, two cytoplasmic adaptor 
proteins, and procaspase-8 to create a complex that is 
located on the inner surface of the plasma membrane. 
FADD and TRADD interact with each other in regions 
known as death domains, and procaspase-8 and 
FADD interact with each other in what are known as 
death effector domains.  Once assembled together, 
the procaspase molecules cleave each other to create 
Caspase-8, an initiator complex that directs the cell to 
its final destination of cell apoptosis.  It is important 
to note, however, that after TRADD binding, two other 
pathways can be initiated.  They will be discussed later. 
Hypothesis and Data
Because neuroinflammation is elevated in the AD 
brain, I hypothesized that neuroinflammation can be 
observed in the MCI brain.  Therefore, TNF-α levels 
are hypothesized to be increased in the MCI brain 
samples.  The results thus far confirm my hypothesis. 
Brain tissue was obtained from five different subjects 
(n = 5) for both control and MCI.  There is a clearly 
significant increase in TNF-α protein levels in MCI. 
(p < 0.01).  There is variation due to the biological 
nature of the samples from human individuals. 
Nuclear Factor-Kappa Beta, NF-κβ
As explained above, after TRADD binding, two other 
pathways other than cell apoptosis can be initiated.  One 
pathway is the activation of NF-κβ .  The other pathway 
is the activation of the MAPK pathways.  The protein 
in this particular study was the p65 subunit of NF-κβ . 
Mechanism
In its normal function, after TRADD binds to the death 
domain, TRADD assembles TRAF2 and RIP, a serine-
threonine containing kinase.  TRAF2 then recruits 
protein kinase, IKK, a multi-component protein.  This 
recruitment permits RIP to activate IKK.  An inhibitory 
protein that is bound to NF-κβ, known as I, inhibits 
NF-κβ from translocation. I is then phosphorylated 
by IKK and is degraded. This process releases NF-
κβ so that it can translocate to the nucleus. NF-κβ is 
a transcription factor that initiates the synthesis of 
proteins that are involved in anti-apoptotic factors, 
(A) Western blot with ten lanes. Lanes 1-5 are control samples. Lanes 
6-10 are MCI samples.  (20 µl of 100 µg samples were added to each well.) 
Lanes 6 and 8 display the significant increase in TNF-α  protein levels. (B) 
Graphical analysis of control and MCI band intensities, respectively. The 
graph illustrates the significant increase in TNF-α from control and MCI 
comparison. (p < 0.01). C-HP, control hippocampus; MCI-HP, MCI hippocampus. 
Figure 2. NF-κβ Protein Levels in Control and MCI Hippocampus
(A) Western blot with eight lanes. Lanes 1-4 are control samples. Lanes 5-8 are MCI 
samples.  (20 µl of 100 µg samples were added to each well.) Lane 6 of MCI clearly 
displays a higher intensity of protein concentration than the control samples and 
illustrates an increase in NF-κβ protein levels in MCI. Lane 7’s value was thrown 
out after a Q-test was performed (B) Lane 1 and 2 are control. Lanes 3-5 are MCI 
samples. (C) Graphical analysis of control and MCI band intensities, respectively. 
The graph illustrates an increase in NF-κβ from control and MCI comparison. C-HP, 
control hippocampus; MCI-HP, MCI hippocampus. (p=0.06; it is near significant)
G e o r G i a n n e  f .  t i ui n s i G h t s  i n t o  a l z h e i m e r ’ s  d i s e a s e :  t h e  l e V e l s  o f 
s i G n a l i n G  P r o t e i n s  i n  B r a i n  o f  c o n t r o l  s u B J e c t s  V e r s u s 
B r a i n  f r o m  s u B J e c t s  W i t h  m i l d  c o G n i t i V e  i m P a i r m e n t
K A L E I D O S C O P E    2  0  0  966
inflammation, and cell survival and proliferation. 
Hypothesis and Data
Because p65 of NF-κβ is a transcription factor that 
mediates the transcription for cell survival and anti-
apoptotic factors, I hypothesized that there will be an 
increase in p65 of NF-κβ in the MCI brain, because 
neuroinflammation and pro-apoptotic factors are expected 
to be increased in the AD brain.  NF-κβ can provide the 
brain with neuroprotection, and if NF-κβ is not released 
into the nucleus, the result will be a lack of important, 
protective proteins.  According to prior research, p50/p65 
of NF-κβ, has been reported to be activated in AD brain 
(Kaltschmidt et al., 1997; Yan et al., 1995; Yoshiyama et 
al., 2001). According to that research, p65 is expected 
to be increased in AD brain.  However, is there an 
increase of p65 in MCI brain? There have been several 
studies that demonstrate that, if NF-κβ is introduced to 
an inhibitor, or even its inhibitory protein, I , is blocked 
with a repressor, the protective effects are nullified. 
Nakao et al. (2008) demonstrated that galantamine 
(a drug that is currently being used to treat mild to 
moderate AD) and its protective effects are nullified with 
the inhibition of NF-κβ or the repression of its bound 
protein, I. This finding suggests that NF-κβ is crucial in 
the reduction of inflammation and the mechanism of 
defense.  Therefore, it is hypothesized that there will be 
an increase in NF-κβ levels in MCI.  My results support 
the hypothesis of a trend toward an increase in NF-κβ 
levels in MCI brain, and the results also illustrate near 
significance as assessed by the Wilcox p-value of 0.06. 
Phospho Bad (Serine 112) (Phos-
phorylated Bcl-2 associated death 
promoter)
Bad is a member of the B cell leukemia-2 (Bcl-2) 
gene family.  When Bad is phosphorylated, it is 
called phospho Bad (p-Bad).  Serine 112 phospho Bad 
was used in this study.  Alterations in phospho Bad 
antagonize apoptosis function in Bad (Jeong et al., 
2007).  Oxidative stress can cause alterations in protein 
expression and perhaps efficiency.  Bad’s main role is 
to signal cell apoptosis to cells that may be damaged, 
from oxidative stress for example.  Phosphorylation 
initiates Bad to signal pro-apoptotic pathways in order 
to rid the brain of damaged components of a cell. 
Mechanism
Oxidative stress is one factor that causes cellular stress 
that ultimately leads to cell apoptosis.  Cellular stress 
causes a pro-apoptotic factor such as Bad to insert itself 
into the outer mitochondrial membrane.  The insertion of 
the protein, Bad, then signals the release of cytochrome 
c molecules from the intermembrane space of the 
mitochondria.  When the cytochrome c molecules are 
translocated to the cytosol, they form a multi-subunit 
complex with caspases that then, in turn, activate the 
downstream executioner caspases that cause apoptosis. 
Hypothesis and Data
Because phospho Bad’s function is to cause cell 
apoptosis, it is hypothesized that there will be a decrease 
in phospho Bad protein levels in MCI brains in order 
to provide neuroprotection from oxidative stress.  The 
reason for this decrease is that when an environmental 
factor, such as oxidative stress, affects the brain cells, 
phospho Bad is signaled to cause pro-apoptotic caspases 
to rid the brain of damaged ells and to regulate the cell 
death processes.  In the normal brain, I hypothesized that 
a decrease in phospho Bad activity or a loss of function 
could result in the aggregation of unwanted proteins.
The data below illustrate no change in phospho 
Bad protein levels in MCI brain, suggesting that these 
unchanging levels contribute to unwanted protein 
accumulation and neuronal toxicity in AD brain.  Yoon et 
al. (2006), support these data, stating that the “cultured 
neurons have shown that okadaic acid (OA) evokes tau 
phosphorylation to initiate a neurodegeneration that 
resembles the pathogenesis of AD.  Western blotting 
revealed that … expression of Bad was decreased 
as early as 4 hours after OA treatment, although the 
level of phospho Bad was relatively constant.”  These 
Figure 3. Phospho Bad Protein Levels in Control and MCI Hippocampus
(A) Western blot with eight lanes. Lanes 1-4 are control samples. Lanes 5-8 are MCI 
samples.  (20 µl of 100 µg samples were added to each well.) (B) Graphical analysis 
of control and MCI band intensities, respectively. The graph illustrates no change from 
control and MCI comparison. C-HP, control hippocampus; MCI-HP, MCI hippocampus. 
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levels were observed in cultured cortical neurons. 
Ubiquitin Carboxyl Terminal Hydro-
lase L1 (UCH-L1)
Ubiquitin C-terminal hydrolase L1 (UCH-L1) is an enzyme 
that is a main component of the ubiquitin proteasome 
system and has catalytic hydrolase properties that can 
hydrolyze peptide-ubiquitin bonds and recycle ubiquitin 
monomers to be used again in the same process (Healy et 
al., 2004).  UCH-L1 is a member of the deubiquitylating 
enzymes and is one of the most abundant proteins 
in the brain.  Whereas other UCH members are 
ubiquitously expressed, UCH-L1 is selectively expressed 
in neurons (Sakurai et al., 2006; Wilkinson et al., 1989). 
Moreover, it is an enzyme involved in the process 
of proteolytic degradation of misfolded or damaged 
proteins by the proteasome (Castegna et al., 2002).
Analysis of proteasome function in post-mortem 
human AD brains has shown a strong inhibition of activity 
in the proteasome and lower protein levels for UCH-L1, 
suggesting that the neuronal ubiquitin-proteasomal 
system is linked to the pathogenesis of AD (Gong et al., 
2006).  Research from our lab also confirmed a decrease 
of UCH-L1 activity in AD brain.  According to Sultana 
et al. (2006), the measurement of enzymatic activity 
of CA II, UCHL-1, and enolase from AD hippocampus 
revealed decreased activity compared to control. 
UCH-L1 is important for proteasomal-mediated 
clearance from the brain of aggregated or misfolded 
proteins.  Protein aggregation, such as tau aggregation, 
is seen in the AD brain.  The decline of UCH-L1 
proteasomal activity likely contributes to protein 
aggregation and thus neuronal toxicity.  Less UCH-L1 
in MCI brain is predicted to result in more ubiquinated 
proteins, decreased activity of the 26S proteasome, 
and consequently, an accumulation of aggregated and 
damaged proteins.  All were observed in MCI brain. 
Because there is evidence of a decline in UCH-L1 
activity in AD brain (Sultana et al., 2006), I hypothesized 
that there will be a decline of UCH-L1 protein levels in the 
MCI brain as well.  The results below support my hypothesis. 
Statistics
For all trials, a Student’s t-Test was performed in order 
to determine significance. Q-test analysis was also 
performed to determine the outliers for statistical analysis. 
The results are presented as the mean plus or minus the 
standard deviation.  Because biological samples were 
used in this project, variation was expected to occur. 
Discussion
Because NF-κβ is downstream from TNF-α, it is 
hypothesized that there will be a proportional relationship 
between the two proteins.  If TNF-α increases in the 
brain, then NF-κβ is expected to increase as well.  The 
increase in oxidative stress creates a signal that anti-
apoptotic factors from NF-κβ need to be synthesized. 
Phospho Bad is pro-apototic, which means 
that it causes cell death.  When TNF-α is activated, 
because of oxidative stress for example, NF-κβis 
activated in order to create proteins that can 
counteract the oxidative stress.  Phospho Bad activates 
downstream caspases that ultimately lead to cell 
apoptosis.  The unchanging levels of phospho Bad 
offer an explanation if there is an accumulation of 
unwanted proteins and neuronal toxicity in MCI.
The unchanging levels of phospho Bad in AD brain 
can be tied to the decrease in UCH-L1 activity.  UCH-L1 
is known to be decreased in AD brain (Castegna et 
al., 2002; Sultana et al., 2006).  This finding means 
that its normal functional levels are decreased and 
therefore lead to histopathological characteristics that 
are evident in the AD brain.  For example, less UCH-L1 
in MCI brain is predicted to result in more ubiquinated 
proteins, decreased activity of the 26S proteasome, 
and, consequently, an accumulation of aggregated 
and damaged proteins.  All are observed in MCI brain. 
UCH-L1 is a member of the deubiquitylating 
family.  It is part of the proteasome pathway that 
Figure 4. UCH-L1 Protein Levels in Control and MCI Hippocampus
(A) Western blot with eight lanes. Lanes 1-4 are control samples. Lanes 5-8 are MCI 
samples.  (20 µl of 100 µg samples were added to each well.) Lanes 1 and 2 (control) 
clearly display higher intensities than the MCI samples and illustrate the significant 
decrease in UCH- L1 protein levels in MCI. (B) Lanes 1 and 2 are control samples. 
Lanes 3-5 are MCI samples. (C) Graphical analysis of control and MCI band intensities, 
respectively. The graph illustrates the significant decrease in UCH- L1 from control and 
MCI comparison. (p < 0.05). C-HP, control hippocampus; MCI-HP, MCI hippocampus. 
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rids the brain of protein aggregations and misfolded 
proteins.  UCH-L1’s down-regulated levels that are 
evident in AD brains contribute to neuronal toxicity, 
because unwanted proteins accumulate in the brain. 
Because oxidative stress signals TNF-α production and, 
therefore, NF-κβ is signaled to produce proteins that help 
to counteract oxidative stress, phospho Bad is signaled 
to induce apoptosis to dispose the damaged proteins. 
UCH-L1 is affected by oxidative stress as well. 
Because UCH-L1’s proteasomal and degradative 
properties are decreased in both MCI and AD brain, 
this means that UCH-L1 cannot rid the brain of 
damaged, unwanted proteins. This failure will 
result in protein aggregation and neuronal toxicity. 
Conclusion
Through this research, new insights into the 
histopathology and biochemical alterations observed 
in MCI brain have been found.  Data presented in this 
paper illustrated that there is an increased level of 
oxidative stress in MCI supported by increased levels 
of TNF-α, NF-κβ, and decreased levels of UCH-L1. 
Phospho Bad’s unchanging protein expression levels 
could mean that there is no activation of pro-apoptic 
pathways stimulated by this pathway, and that could lead 
to an accumulation of damaged components in brain. 
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